AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received a $338,387 Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Health. Under the 2 year grant, AmideBio will develop and produce a series of solution-stable glucagons and test them both in vitro and in vivo with the goal of identifying a glucagon analog suitable for clinical testing for long term treatment of hyperinsulinism, a disease whereby infants and new born babies suffer from persistant hypoglycemia which can lead to seizures and brain damage. A solution-stable glucagon would also have benefit in the treatment of emergency hypoglycemia.

Glucagon has been shown to be an effective treatment option for hyperinsulinism but its inherent instability has limited its therapeutic use due to complications associated with its administration through pumps. Using AmideBio’s BioPure™ process, the Company has produced glucagon analogs that have in-use stability of at least 6 months at 40°C and extended long term storage that meets the standard 95% potency requirement throughout 2-year storage at 4°C. These analogs will be suitable for use in a pump system for long-term management of severe persistent hyperinsulinism. Under the grant, these analogs will be further refined and tested.

“This grant will allow us to further develop and test AmideBio’s stable glucagons for treatment of patients with hyperinsulinism who fail to respond to current drug treatments,” said Misha Plam, CEO of AmideBio. “This therapeutic solution offers the potential for babies to avoid traumatic surgeries including a total pancreatectomy, providing the chance for them to live more normal lives.”

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease

Blood-based test offers more precise treatment prognosis to inform treatment choice, improve physician-patient communication, and address payment program quality measures
 

Continue Reading